RPG Life Sciences Peer Comparison

NSE: RPGLIFE | BSE: 532983

₹2,719.20

₹-92.50 (-3.29%)

As on 09-Oct-2026IST

Market cap

₹4,500 Cr

Revenue (TTM)

₹734 Cr

P/E Ratio

37.7

P/B Ratio

7.1

Div. Yield

0.9 %

Edit

	RPG Life Sciences	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	4,500	34,811	26,789	16,287	14,258
Revenue (₹ Cr)	734	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	119.45	1,018.97	497.77	603.02	270.18
Net Margin (%)	15.74	10.47	20.72	22.63	23.29
RoE (%)	20.13	21.30	28.49	19.61	14.45
Price to Earnings	37.67	34.42	53.82	27.01	51.78
Price-To-Book	7.08	6.66	13.25	4.67	6.88

Income Statement (₹ Cr)

	RPG Life Sciences	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	707.52	9,203.54	2,022.99	2,551.83	1,054.89
Total Income	733.10	9,335.01	2,053.15	2,612.24	1,107.25
Total Expenditure	559.55	7,457.80	1,448.49	1,754.55	686.95
EBITDA	147.97	1,745.74	574.50	797.28	367.94
Depreciation	21.48	415.05	91.74	75.36	74.46
EBIT	126.49	1,330.70	482.76	721.93	293.48
Interest	1.77	143.67	23.95	5.37	0.82
Other Income	25.58	131.47	30.17	60.41	52.36
Exceptional Items	3.90	-31.35	76.40	-25.66	-3.28
Profit before Tax	154.20	1,287.14	488.98	751.31	344.65
Provision for Tax	39.03	345.87	124.98	186.83	85.42
Profit after Tax	115.17	941.27	364.00	564.48	259.23

	RPG Life Sciences	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	605.35	4,950.03	1,874.47	3,332.13	2,017.06
Minority Interest	--	26.64	--	--	-1.92
Non-Current Liabilities	27.24	584.19	345.47	142.73	47.58
Current Liabilities	160.57	3,912.24	710.20	682.24	169.08
Total Liabilities	793.16	9,514.48	2,930.14	4,157.10	2,231.79

	RPG Life Sciences	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	233.68	3,861.01	1,447.01	1,333.54	981.68
Current Assets	559.48	5,612.10	1,483.13	2,823.56	1,250.11
Total Assets	793.16	9,514.48	2,930.14	4,157.10	2,231.79
Total Debt*	20.00	1,204.08	196.61	0.00	0.00
Net Current Assets	398.91	1,699.86	772.93	2,141.33	1,081.03
Contingent Liabilities	17.79	258.92	13.18	4.82	3.76

	RPG Life Sciences	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	56.50	943.55	346.68	565.41	266.88
Cash Flow from Investing Activities	85.84	-1,193.06	-423.73	-570.15	-142.72
Cash from Financing Activities	-20.58	343.43	20.98	-64.34	-112.88
Net Cash Inflow / Outflow	121.76	93.92	-56.08	-69.08	11.28

	RPG Life Sciences	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	26.99	25.25	27.50	24.61	18.04
ROE (%)	20.28	20.09	21.43	18.41	13.54
ROA (%)	15.89	10.70	14.25	14.27	12.15
EBIT Margin (%)	24.53	20.40	29.89	33.61	39.84
Net Margin (%)	15.71	10.08	17.73	21.61	23.41
Cash Profit Margin (%)	18.06	14.44	22.53	24.81	31.63

	RPG Life Sciences	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	8.28	16.56	36.98	6.91	-12.10
EBIT Growth (%)	0.14	21.77	75.89	19.60	-23.76
Net Profit Growth (%)	-37.15	33.05	39.94	16.24	-30.25
EPS Growth (%)	-37.15	35.59	39.94	16.05	-29.80
Book Value Growth (%)	14.10	11.36	22.95	18.43	11.27

	RPG Life Sciences	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	26.57	32.73	42.34	21.18	40.73
Price / Book Value	5.05	6.13	8.23	3.60	5.27
Dividend Yield (%)	1.30	0.23	0.28	0.51	0.74
EV/EBITDA	16.64	16.68	25.23	13.94	25.25
Market Cap (₹ Cr)	3,059.67	30,257.56	15,412.11	11,956.86	10,627.92

	RPG Life Sciences	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.03	0.24	0.10	0.00	0.00
Short term debt to equity ratio	--	0.16	--	--	0.00
Current Ratio	3.48	1.43	2.09	4.14	7.39
Quick Ratio	2.71	0.82	1.37	3.12	5.46
Interest Coverage	88.12	9.96	21.42	140.86	419.57

	RPG Life Sciences	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	16.49	27.84	26.76	42.05	43.63
Asset Turnover	1.04	1.07	0.79	0.65	0.49
Receivable days	49.08	88.68	77.32	144.58	169.86
Inventory Days	52.31	84.11	80.83	96.67	97.92
Payable days	138.22	176.65	125.94	135.45	159.68
Cash Conversion Cycle	-36.84	-3.86	32.22	105.80	108.11

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.